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Abstract TuCa1, an ascidian homolog of L-type Ca channel
K1-subunit, has many critical sites required for binding 1,4-di-
hydropyridines (DHPs), but is insensitive to DHPs and methyl
2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carbox-
ylate (FPL-64176). We have substituted Ser for Ala1016 at the
P-region of domain III in TuCa1 (TuCa1/A1016S) and func-
tionally expressed the channel in Xenopus oocyte along with
rabbit K2/N and L2b. TuCa1/A1016S has gained DHP sensitivity
as high as that of a mammalian neuronal L-type Ca channel
(rbCII), but remained resistant to FPL-64176. These results
reinforce the view that Ser1016 in TuCa1/A1016S participates
in DHP binding, but there exist other novel sites that fully
acquire sensitivity to FPL-64176.
4 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Voltage-dependent Ca channel gets opened by membrane
depolarization and selectively permeates Ca, thus modulates
a variety of cellular functions such as synaptic transmission,
secretion, and muscle contraction [1]. Ca channels are com-
plex proteins that consist of a pore-forming K1 subunit, disul-
¢de-linked transmembrane complex of K2 and N subunits (K2/
N), intracellular L subunit, and Q subunit [1,2]. K1 subunits are
further divided into ¢ve major subtypes based on biophysical
and pharmacological characteristics : L (K1C(CaV1.2),
K1D(CaV1.3), K1S(CaV1.1), K1F(CaV1.4)) ; N (K1B(CaV2.2)) ;
P/Q (K1A(CaV2.1)); R (K1E(CaV2.3)); and T (K1G(CaV3.1),
K1H(CaV3.2), K1I(CaV3.3)) [3,4]. Dihydropyridine (DHP) is a
classical Ca2þ channel antagonist that binds to L-type Ca2þ
channel K1 subunits with high a⁄nity [5,6].
We have cloned TuCa1, a homolog of L-type Ca channel
K1 subunit, from the tadpole of ascidian species, Halocynthia
roretzi [7]. TuCa1 conserves nearly all of the sites that are
crucial for binding DHP [7]. However, the channel is insensi-
tive to DHPs [8]. A number of amino acid sequences of
TuCa1 are di¡erent in the conserved region of mammalian
K1 subunits, which include DHP-insensitive types. Based on
this observation, Ser1115 has been substituted with Ala in
the pore-forming region (P-region) between IIIS5 and IIIS6
of rbCII (CaV1.2) [9]. This substitution has remarkably de-
creased sensitivity of the channel to DHPs and methyl 2,5-
dimethyl-4-[2-(phenylmethyl)benzoyl]-1H-pyrrole-3-carboxyl-
ate (FPL-64176), a benzoylpyrrole-type Ca channel agonist
[9].
In the present study, we have reversed substitution of ami-
no acids in TuCa1 from ascidian type to a mammalian type.
We show that a single amino acid substitution of TuCa1
recovers full sensitivity to DHP agonist, but not to FPL-
64176.
2. Materials and methods
2.1. Site-directed mutagenesis in TuCa1
TuCa1 in pSD64TF, a modi¢ed version of pSP64 (Promega, Mad-
ison, WI, USA), was kindly provided by Dr. T.P. Snutch [7]. To
replace Ala1016 with serine (A1016S), a sense primer CTGACGCTCT-
TTGTTGTTTCTACGTTCGAAG (A1016Sforward) was designed
with its antisense primer CTTCGAACGTAGAAACAACAAAGA-
GCGTCAG (A1016Sreverse). The bold letter indicates a change
from the wild-type TuCa1 sequence. After ampli¢cation of AvrII
(2520)-A1016Sreverse and A1016Sforward-AccI(4117) fragments, the
AvrII-AccI fragment was ampli¢ed from the two fragments above and
subcloned into pCR2.1 using TA Cloning Kit (Invitrogen, San Diego,
CA, USA). The MunI(2928)-AccI fragment of the plasmid was intro-
duced into IIIS5-S6 linker of TuCa1-pBluescript and the full-length
TuCa1/A1016S was inserted into pSD64TF via NotI and KpnI.
2.2. RNA injection into Xenopus oocytes
The above plasmids were linearized with SalI, transcribed by SP6
RNA polymerase, and injected into Xenopus oocyte. The cDNA
clones that were co-expressed with either the wild-type or mutant
TuCa1 were comprised of pBH17, a rabbit L2b subunit (#X64298)
kindly provided by Dr. V. Flockerzi [10], and pSPCA1, a rabbit
K2/N subunit (#M21948) kindly provided by Dr. T. Tanabe [11,12].
Rat brain K1C subunit (rbCII, CaV1.2c, #M67515), kindly provided
by Dr. T.P. Snutch [13], in pSD64TR [14] was co-expressed with L2b
and K2/N as a control.
Xenopus oocytes were prepared as described previously [7]. The
concentration of the injected synthetic RNA of K1 subunits was
0.5 ng/nl. The concentration of the injected L2b and K2/N subunits of
rabbit VDCC was 0.25^0.5 ng/nl. The injected volume of RNA solu-
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tion was 50^100 nl per oocyte. The oocytes were incubated for 2^
5 days at 18‡C prior to recording.
2.3. Electrophysiology of Xenopus oocytes
The electrical activity of oocytes was recorded as described previ-
ously [7]. To record Ba2þ currents, bath solution was composed of the
following (in mM): Ba(OH)2, 20; NaOH, 35; KOH, 2; methane
sulfonate, 77; HEPES, 5; ni£umic acid, 0.5 (pH 7.4). To eliminate
Cl current that gets activated by divalent cations, 50 nl of 50 mM
Na4BAPTA with 10 mM HEPES (pH 7.0) was microinjected into
each oocyte 5^30 min before the recording [15]. The currents were
recorded and analyzed with Pulse+PulseFit 8.09 (Heka Elektronik,
Lambrecht/Pfalz, Germany) and IGOR Pro Ver 3.0 (WaveMetrics,
OR, USA), respectively. The results are presented as meansTS.E.M.
2.4. Materials
S-(-)-Bay k 8644 (1,4-dihydro-2,6-dimethyl-5-nitro-4-[2-(tri£uoro-
methyl)-phenyl]-3-pyridine carboxylic acid methyl ester) and FPL-
64176 (Sigma Chemical Co., St. Louis, MO, USA) were dissolved in
EtOH and stored at 320‡C as 3 mM stock solutions. Each drug was
previously diluted into a 10th of the ¢nal concentration and was
directly added to the bath solution.
3. Results
3.1. Electrophysiological properties of TuCa1 and
TuCa1/A1016S
We replaced Ala1016 with Ser in IIIS5-S6 linker of TuCa1,
which is the opposite of the previous experiment, in which
Ser1115 in rbCII was replaced with Ala [9]. Ser is conserved
in K1A, K1B, K1C, K1D, K1E and K1S, but not in TuCa1 or
CyCaK1, a jelly¢sh K1 Ca channel. We unexpectedly found
that both the wild-type and mutant TuCa1 have a deletion
of T at 2903, which might cause a frame shift just before
domain III and a truncation at Arg826 (Fig. 1). Despite the
mutation, these clones were functionally expressed in Xenopus
oocyte. This point will be discussed later.
Either the wild-type or mutant TuCa1 generated currents
when co-expressed with accessory subunits, namely, rabbit L2b
and rabbit K2/N in Xenopus oocyte. We used Ba2þ ions as
Fig. 1. A: Partial nucleotide sequence of TuCa1 or TuCa1/A1016S which has a deletion of T2903 (b) in this study is aligned with that of normal
TuCa1 (a) (accession number AB013604). B: Frame shift and truncation caused by the deletion of T2903 and a proposed restart site of the
C-terminal half of TuCa1 are illustrated (b). Normal TuCa1 (a) is aligned with the frame-shift mutant. Transmembrane segments are boxed.
Identical nucleotide and amino acid between the mutant and normal TuCa1 are indicated with an asterisk.
Fig. 2. Electrophysiological properties of Ba2þ currents derived
from wild-type TuCa1 or TuCa1/A1016S co-expressed with rabbit
L2b and K2/N in Xenopus oocyte. A: (a) Representative Ba2þ current
of TuCa1 and TuCa1/A1016S. Protocol for voltage clamp is shown
at the top. (b) Ba2þ currents at 310 mV of TuCa1 (gray) and
TuCa1/A1016S (black). The traces were normalized and superim-
posed. B: Current^voltage relationship (I^V) (a), ratios of current
amplitude at the end of step pulse (200 ms) to peak amplitude (b)
and time to reach half of the peak current amplitude during the
step pulses of 200-ms interval (c) plotted against membrane poten-
tial. Open and closed circles indicate wild-type and mutant TuCa1,
respectively. In (a)^(c), n=4 for TuCa1, n=5 for TuCa1/A1016S.
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current carriers in order to reduce Ca2þ-dependent inactiva-
tion. A comparison of kinetics between both channels is
shown in Fig. 2. The current^voltage relationship (I^V) re-
vealed that the peak current amplitude of TuCa1/A1016S
was found around 0 mV, which was shifted to the right of
that of wild-type TuCa1 (Fig. 2B(a)). However, both channels
showed almost the same kinetics (Fig. 2B(b,c)). Furthermore,
superimposed traces of the normalized current show an iden-
tical waveform when voltage-clamped at 310 mV (Fig. 2A).
3.2. TuCa1/A1016S gained DHP sensitivity
The Ba2þ current amplitude increased (1.43T 0.14)-fold in
rbCII with the application of 8 WM S-(-)-Bay k 8644, a DHP
agonist (Figs. 3C and 4A), but decreased with either 8 WM
nitrendipine or nifedipine, the DHP antagonists (data not
shown). Because 8 WM agonist optimally enhanced the
rbCII-derived current in Xenopus oocyte (data not shown),
all experiments were performed under the same condition.
Wild-type TuCa1 was unresponsive to S-(-)-Bay k 8644 (Fig.
3A) and a slight decline of the current was observed (Fig. 4A,
(0.89T 0.06)-fold). Wild-type TuCa1 was also resistant to
4 WM nifedipine and 8 WM nitrendipine (data not shown).
In contrast, TuCa1/A1016S signi¢cantly increased sensitivity
to DHP, similar in fashion to rbCII; the current amplitude
increased by (1.49T 0.21)-fold with the application of agonists
(Fig. 3 and 4B) and decreased with antagonists (data not
shown). The magnitude of changes in current amplitudes
was as great as that in rbCII. In addition, TuCa1/A1016S
showed leftward shifts in the I^V and peak current amplitude
(Fig. 4C). Deceleration of deactivation kinetics is another
hallmark of DHP action on L-type calcium channel. Thus,
the deactivation kinetics was analyzed by measuring the decay
time constant of tail currents. Both TuCa1 and TuCa1/
A1016S currents were ¢tted by a single exponential, whereas
rbCII was ¢tted by a double exponential (Fig. 4B(b)). Upon
application of S-(-)-Bay k 8644, TuCa1/A1016S showed about
¢ve-fold increase in the time constant (Fig. 4B(a)).
3.3. Current amplitude of TuCa1/A1016S was not enhanced by
FPL-64176
FPL-64176, a benzoylpyrrole-type Ca channel agonist,
binds to the Ca channel at a di¡erent binding site than
DHPs [16]. It has been reported that rbCIIS1115A only
weakly enhances the current with an application of FPL-
64176 and DHP agonist compared to the wild-type rbCII
channel [9]. In our study, FPL-64176 increased the current
of wild-type rbCII by (1.84T 0.77)-fold (Figs. 5C and 6),
which is a greater increase than S-(-)-Bay k 8644. However,
application of 10 WM FPL-64176 did not enhance the current
of the wild-type TuCa1 ((0.95T 0.02)-fold, Figs. 5A and 6)) or
TuCa1/A1016S ((1.04T 0.1)-fold, Figs. 5B and 6)). TuCa1/
A1016S showed a mild deceleration of the tail current with
an application of FPL-64176 (Fig. 6A).
4. Discussion
The wild-type and mutant TuCa1 clones unexpectedly
Fig. 3. Representative traces of Ba2þ currents derived from TuCa1
(A), TuCa1/A1016S (B) and rbCII (C) in the absence (a) or pres-
ence (b) of 8 WM S-(-)-Bay k 8644 activated by the protocol shown
in Fig. 2A(a). The peak current in each panel is traced in black.
Fig. 4. E¡ects of 8 WM S-(-)-Bay k 8644 on peak current amplitudes
(A), time constant of deactivation (B), and I^V (C) of Ba2þ current
derived from TuCa1, TuCa1/A1016S and rbCII. A: Each bar indi-
cates the peak current amplitude with presence of agonist, normal-
ized by amplitude without. B: (a) Tail currents at 370 mV after the
step pulse (50 ms, 50 mV) were analyzed by single (TuCa1 and
TuCa1/A1016S) or double (rbCII) exponential ¢t. Time constants
are plotted against membrane potential before (white) and after
(black) the application of the agonist. Number of cells is indicated
above the bars. (b) Representative examples of exponential ¢t of the
tail current of TuCa1/A1016S and rbCII either before (bold curve)
or after (dotted curve) agonist application. C: I^V relations of Ba2þ
current before (white) and after (black) the application of agonist.
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showed a deletion of T at 2903, which may cause a frame shift
and truncation at Arg826 (Fig. 1A). However, these clones are
functionally expressed and acquired DHP sensitivity by the
mutation of Ala1016 downstream of a site that corresponds
to the frame shift. One possibility that accounts for a func-
tional expression is that a complementary polypeptide gets
translated from a Met site downstream of the site of frame
shift (Fig. 1B), which then co-assembles with the truncated
polypeptide and forms a complete channel. It has been re-
ported on cloned Cav1.1 that two polypeptides get produced
from a frame-shifted RNA and successfully reconstitute gat-
ing charges in the muscle cell of dysgenic mouse [17]. Another
possible mechanism is RNA polymerase slippage, which is
reported to occur in Escherichia coli dnaX mRNA [18]. In
fact, the frame shift occurs in the poly Ts (6 Ts) in TuCa1
plasmids, whereas the RNA polymerase slips at a run of 9 Ts
in dnaX. This phenomenon is probably worth another detailed
study, yet we choose not to investigate beyond this point in
this paper. It is unlikely that this phenomenon a¡ects the
major conclusions of this study.
DHP-binding sites have been determined by photo-a⁄nity
labeling, radio-ligand binding, chimera, and alanine-scanning
mutagenesis based on sequence di¡erences between K1C (or
K1S) and DHP-insensitive K1A subunit [19^23]. Alanine-scan-
ning mutagenesis of IIIS6 and IVS6 has shown that some
conserved amino acids in K1C and K1A are required for
high-a⁄nity binding of Ca channel antagonists [24]. Recently,
substitutions of Ala for Phe1112, Ser1115 or both in the IIIS5-
S6 linker of rbCII have been shown to reduce the sensitivity
to DHPs and FPL-64176 [9,25]. Phe, but not Ser, is conserved
in TuCa1 and jelly¢sh CyCaK1, both of which are DHP-in-
sensitive [9]. In this study, we have shown that reverse muta-
tion from Ala1016 to Ser increases DHP sensitivity in TuCa1
as much as that observed in rbCII (Figs. 3 and 4). This result
reinforces the view that the Ser in the pore region is a critical
determinant for DHP actions.
FPL-64176 and Bay k 8644 are known to bind to di¡erent
sites on the Ca channel [26,27] and they interact with each
other allosterically [16,28,29]. TuCa1/A1016S showed high
DHP sensitivity, but did not show increase in the current
amplitude by FPL-64176 (Figs. 5 and 6). However, tail cur-
rent kinetics of TuCa1/A1016S became slightly slower by
FPL-64176, suggesting its mild agonist action. It is thus un-
likely that TuCa1/A1016S fails to bind FPL-64176. To gain
full agonist action of FPL-64176, Ser and Phe [25] in the
P-region of domain III may need to interact with other novel
amino acid(s) that is (are) not conserved in TuCa1.
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